GT BIOPHARMA, INC. Non Peo Neo Avg Total Comp Amt
GT BIOPHARMA, INC. (GTBP) reported Non Peo Neo Avg Total Comp Amt of $739.31 thousand for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-07-02.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-07-02
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $739.31K DEF 14A · filed 2026-07-02 |
| 2024-12-31 | $377.78K DEF 14A · filed 2026-07-02 |
| 2023-12-31 | $1.13M DEF 14A · filed 2026-07-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |